Bristol-Myers Squibb signed a licensing agreement to develop a once-daily HIV tablet that would combine
the firm's protease inhibitor Reyataz and Gilead Sciences' experimental booster cobicistat. Gilead began
Phase II and III tests on newly diagnosed patients. If the combination therapy is commercialized, Bristol will pay Gilead royalties.

Full Story:

Related Summaries